AU
UK
CA
NZ
IND
US
Mesoblast (Nasdaq: MESO) has confirmed that its allogeneic cellular products, including Ryoncil® and Revascor®, will be exempt from U.S. tariffs. This exemption is made possible because the company’s products are designated as “U.S. Country of Origin” products. All products are manufactured using U.S. donors …
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. Whitaker's appointment brings a wealth of knowledge and experience to the company, stemming from over three decades in the pharmaceutical, biotech, and specialty pharmaceutical sectors.
Long-Lasting Effect:A 400 mg dose sustained a 91.0% reduction for a year and 74.2% reduction for 1.5 years.
Expanded Access:Ryoncil® will be available to 40% of U.S. children covered by Medicaid with steroid-refractory acute graft versus host disease (SR-aGvHD).
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing and manufacturing authorization for Dupixent® (dupilumab) to treat chronic obstructive pulmonary disease (COPD) in adults whose condition is not well-managed with existing therapies. This …
Lacutamab granted FDA Breakthrough Therapy Designationfor relapsed or refractory Sézary syndrome.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced significant progress in the development of its proprietary antisense oligonucleotide (ASO) drug candidate, HT-KIT. The biopharmaceutical company is focused on creating therapies for allergic and inflammatory diseases, and HT-KIT represents an innovative approach to treating conditions such …
Highlights
Opthea Limited (NASDAQ:OPT), a clinical-stage biopharmaceutical company, has announced the results of its global Phase 3 COAST (Combination OPT-302 with Aflibercept Study) trial, which evaluated the combination therapy of sozinibercept and aflibercept for the treatment of wet age-related macular degeneration (wet AMD). The trial …
Please wait processing your request...